EFPIA Perspectives

Richard Bergström
Director General
The challenge

R&D EXPENDITURE – OUTPUT RETURN ON INVESTMENT 1970-2007

1 Includes NCEs and BLAs. BLAs included 1996 onward; biologics approvals in prior years assumed negligible

The **European Union and the pharmaceutical industry** have joined forces to make drug R&D processes in Europe more efficient and effective and enhance Europe’s competitiveness in the sector.
Vision

Make **drug R&D processes in Europe more efficient and effective** and **enhance Europe’s competitiveness in the sector**

Idea generation  
Basic research and non-clinical testing  
Human testing  
Regulatory approval and Health Technology assessment  
Marketed drug

To the benefit of EU: Improved healthcare status of individuals and society, and positive economical impact  
To the benefit of Pharma Industry: facilitate development of next generation drugs

Open Information Day – 17 June 2011 - Brussels
Overview Call 4

Cluster 1: EU Medical Information System

1. Building up a European Medical Information Framework to improve healthcare and facilitate research
2. ETIKS: European Translational Research Infrastructure & Knowledge Management Services

Cluster 2: Chemistry, Manufacturing and Control

3. Delivery and Targeting Mechanisms for Biological Macromolecules
4. In vivo predictive biopharmaceutics tools for oral drug delivery
5. Sustainable Chemistry – Delivering Medicines for the 21st Century

Cluster 3: Technology and Molecular Disease Understanding

6. Human Induced Pluripotent Stem (hiPS) Cells for Drug Discovery and Safety Assessment
7. Understanding and Optimising Binding Kinetics in Drug Discovery

Open Information Day – 17 June 2011 - Brussels